Top Medical Stocks To Invest In 2014

Shares of Johnson & Johnson (JNJ) are trading up 0.4% at $90.18 at 1:38 p.m. today after the healthcare giant reported better-than-forecast earnings.

Associated Press

Reuters has the details on Johnson & Johnson’s numbers:

Excluding special items, J&J earned $1.36 per share. Analysts on average, had expected $1.32 per share, according to Thomson Reuters I/B/E/S. The company took special charges of about $900 million in the quarter, related largely to legal expenses and merger-related costs…

Global drug revenue jumped almost 10 percent to $7.04 billion…But sales of the company’s medical devices were hurt by patients’ continuing reluctance to undergo elective surgeries and other procedures in a weak economy. Division sales fell 2 percent to $6.93 billion.

Color S&P Capital IQ’s Herman Saftlas impressed. He writes:

5 Best Recreation Stocks For 2015: Senesco Technologies Inc (SNTI)

Senesco Technologies, Inc., incorporated on September 30. 1999, is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants.

Human Therapeutic Applications

The Company has developed a therapeutic candidate, SNS01-T, an improved formulation of SNS01, for the potential treatment of multiple myeloma and non-Hodgkin B-cell lymplomas. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid (pDNA), expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50, (eIF5AK50R), and a small inhibitory RNA (siRNA). These two components are combined in a fixed ratio with a polymer, polyethyleneimine (PEI), which enables self-assembly of the DNA and RNA into nanoparticles with demonstrated enhanced delivery to tissues and protection from degradation in the blood stream. The Company has also demonstrated that the combination of lenalidomide and SNS 01-T performs better than either treatment alone in mouses xenograft models of human mantle cell lymphoma. The Company's human therapeutic research program, which consists of pre-clinical in-vitro and in-vivo experiments designed to assess the role and mode of action of Factor 5A in human diseases and a phase 1a/2b clinical trial.

The Company competes with Celgene, Inc., Takeda/Millennium, ONYX Pharmaceuticals, Inc., Amgen Inc., Janssen Biotech, Inc., Novartis AG, and Pharmacyclics, Inc.

Agricultural Applications

The Company's agricultural research focuses on the discovery and develo! pment of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops. The Company's research and development initiatives for agriculture include develop and implement the DHS and Factor 5A gene technology in banana, canola, cotton, turfgrass, rice, alfalfa, corn, soybean and trees; and test the resultant crops for new beneficial traits such as increased yield, increased tolerance to environmental stress, disease resistance and more efficient use of fertilizer.

The Company competes with Mendel Biotechnology, Renessen LLC, Exelixis Plant Sciences, Inc., and Syngenta International AG.

Advisors' Opinion:

• [By CRWE]

  Today, SNTI has shed (-2.44%) down -0.0010 at $.0400 with�723,673 shares in play thus far (ref. google finance Delayed: 2:58PM EDT October 7, 2013).

  Senesco Technologies, Inc. previously reported it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross proceeds through the sale of 69,000,000 shares of its common stock. The common stock was priced at $0.025 per share.

  The offering is expected to close on or about October 2, 2013, subject to customary closing conditions. The net proceeds of the financing will be used primarily for working capital, research and development and general corporate purposes.

Top Medical Stocks To Invest In 2014: Cadus Corp (KDUS)

Cadus Corporation (Cadus), incorporated in January 23, 1992, has a wholly owned subsidiary, Cadus Technologies, Inc. (the Subsidiary), which holds all patents, patent applications, know how, licenses and drug discovery technologies of the Company. The Company maintains all its strains, as well as a biological database that catalogues its collection of cells, cell lines, yeast strains and genetic engineering tools. This database has approximately 30,000 entries, which include the phenotype and the genotype of the cell or yeast strain and its storage site. As of December 31, 2011, the Company had no internal or external drug discovery operations.

Yeast

The Company has developed technologies based on yeast that are useful in identifying drug discovery candidates targeted at G Protein-coupled receptors. Yeast is a single-celled microorganism that is used to make bread, beer and wine. Both yeast and human cells consist of a membrane, an intracellular region and a nucleus containing genes. The genes in yeast express proteins, including cell-surface receptors, such as G Protein-coupled receptors and signaling molecules, such as protein kinases, that are similar to human proteins.

Hybrid Yeast Cells

The Company developed a technology to insert human genes into yeast cells to create hybrid yeast cells. Its scientists created hybrid yeast cells by replacing yeast G Protein-coupled receptor genes and certain signaling molecules with their human equivalents. As a result, these hybrid yeast cells express a human G Protein-coupled receptor and a portion of its signaling pathway. These hybrid yeast cells can be used to identify those compounds that act as agonists or antagonists to that receptor or a molecule that is in its signaling pathway. The Company designed and developed more than 25 thousand genetically different yeast strains that can be used to build hybrid yeast cells (the Yeast System).

The Company competes with Glaxo Smith Kline, Plc.

Advisors' Opinion:

• [By Geoff Gannon] cash producing business like ADDvantage (AEY) that happens to be overcapitalized. I'd much rather own a business with real earnings rather than wait for something to happen with a pile of cash.

  My question is this: How cheap is cheap enough? Clearly (to me), George Risk (RSKIA) is cheap at or even just above book value. It's a darn good business so I'm getting high quality assets and earnings power. That gets less clear when looking at lower quality businesses.

  For example:

  Solitron (SODI) sells at 74% of NCAV, has decent z- and f-scores, a FCF margin of 5.3% and an ROA of 12%.

Top Medical Stocks To Invest In 2014: Kite Pharma Inc (KITE)

Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient�� own immune system to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT). eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs, or T cell receptors, or TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Company funds multiple Phase I-2a clinical trials with CAR- and TCR-based therapies that are being conducted by its collaborator, the Surgery Branch of the National Cancer Institute (NCI). The Company plans to conduct a Phase I-2 clinical trial for its lead product candidate KTE-C19, a CAR-based therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).

eACT involves harvesting T cells from the patient�� blood; genetically engineering T cells to express cancer-specific receptors; increasing the number of engineered T cells and infusing the functional cancer-specific T cells back into the patient. Using eACT technology, T cells can be genetically modified to express one of two classes of cancer-specific receptors: CARs or TCRs. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. TCRs broaden the therapeutic approach by recognizing fragments on the cancer cell surface derived from intracellular proteins. By combining both CAR and TCR approaches, it has the potential to generate a portfolio of products that can target both solid and hematological tumors. It has a Cooperative Research and Development Agreement (CRADA), through which it is funding the research and development of eACT-based product candidates utilizing CARs and TCRs for the treatment of advanced solid and hematological malignancies.

The Company�� lead product candidate, KTE-C19, ! is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias. The Company is an ongoing NCI Phase I-2a clinical trial utilizing anti-CD19 CAR T cell therapy that is designed to establish a dose level and appropriate conditioning regimen, as well as to assess overall safety, in patients with B cell lymphomas and leukemias that had been heavily pretreated and were relapsed/refractory (unresponsive) to chemotherapy. KTE-C19 will use the identical anti-CD19 CAR construct and viral vector that is being used in the NCI trial. The Company a license with the NIH for intellectual property relating to a TCR-based T cell therapy targeting the antigen SSX2 for the treatment of head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer and sarcoma, and a co-exclusive license to this intellectual property for the treatment of certain additional cancer types.

Advisors' Opinion:

• [By Matt Egan]

  While the health-care sector only raised $1.8 billion during the second quarter, it led the way with 24 IPOs, up from 17 the year before. Hot drug IPOs include Zs Pharma (ZSPH), Kite Pharma (KITE) and GlobeImmune (GBIM), all of which debuted in June and are trading more than 40% above their IPO price.

• [By John Udovich]

  Biotech news this week was dominated by a number of healthcare and biotech related IPOs, including Parnell Pharmaceuticals Holdings Ltd (NASDAQ: PARN), Signal Genetics Inc (NASDAQ: SGNL), ZS Pharma Inc (NASDAQ: ZSPH), Ardelyx Inc (NASDAQ: ARDX)�and Zafgen Inc (NASDAQ: ZFGN) with Kite Pharma Inc (NASDAQ: KITE), Microlin Bio Inc (NASDAQ: MCLB) and�Syndax Pharmaceuticals Inc (NASDAQ: SNDX) presumably set to debut today (Note:�See�This Week�� Biotech IPOs: Two Losers and One Winner So Far (PARN, SGNL & ZSPH)):

• [By John Udovich]

  Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Top Medical Stocks To Invest In 2014: KaloBios Pharmaceuticals Inc (KBIO)

KaloBios Pharmaceuticals, Inc., is a United States-based company, which develops protein therapeutics. The Company develops and engineers antibodies and protein therapeutics. Its monoclonal antibodies (mAbs) technology that is being used for reengineering antibodies with products being developed in the areas of infectious disease, autoimmunity, and oncology. Its suite of technologies can also be used for discovery and engineering of other proteins, industrial enzymes and small molecule drugs. It conducts three clinical development programs in leukemia, infectious diseases, and autoimmune diseases. Advisors' Opinion:

• [By Monica Gerson]

  KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) shares fell 64.48% to $0.65 in pre-market trading after the company reported top-line data from phase 2 study of KB001-A.